Lightlake Therapeutics has appointed Mark Ellison executive vice president development, manufacturing and quality. His appointment is part of a process to accelerate drug development at Lightlake following U.S. Food and Drug Administration (FDA) approval of the company’s first product, Narcan Nasal Spray, by Lightlake’s commercial partner, Adapt Pharma. “With Adapt’s success in obtaining marketing approval for Narcan Nasal Spray we are now focused on accelerating advancement of our drug devel...